The Future of Biotech: Insights into Perceptive Advisors LLC's Q3 to Q4 2022 Holdings Comparison
Ava Hoppe | 2 May, 2023
Perceptive Advisors LLC, the biotech-focused hedge fund, made significant changes in its holdings between Q3 and Q4 of 2022. While some companies saw an increase in shares owned, others saw a drastic drop. In this article, we'll take a closer look at the changes and what they could mean for the future of biotech.
Starting with the increases, Amylyx Pharmaceuticals Inc (AMLX) had the most significant jump, with Perceptive Advisors LLC increasing its shares from 5,472,033 to 6,088,333. This 46% increase in holdings could indicate that Perceptive Advisors LLC is bullish on Amylyx's products, which focus on treating neurodegenerative diseases.
Madrigal Pharmaceuticals Inc (MDGL) also saw a sizeable increase in shares, with Perceptive Advisors LLC upping their holdings from 331,023 to 731,932. This 887.5% increase in holdings marks a significant investment in the clinical-stage biopharmaceutical company that specializes in treating patients with liver, cardiovascular, and metabolic diseases.
Verona Pharma plc (I9SA.HA) saw their shares increase from 5,047,264 to 4,880,719, a 147.2% increase. This increase could be due to Verona Pharma's development of a new treatment for respiratory diseases, which recently received a favorable review from the FDA.
Moving on to the decreases, Mirati Therapeutics Inc (MRTX) saw the most significant drop in holdings, with Perceptive Advisors LLC decreasing its shares from 2,784,796 to 2,191,425. This 48.9% decrease could indicate that Perceptive Advisors LLC has lost confidence in Mirati Therapeutics' cancer treatments.
Bellus Health Inc New (BLU.TO) also saw a significant drop in shares, with Perceptive Advisors LLC decreasing its holdings from 10,247,073 to 8,891,027. This 32.5% decrease could be due to Bellus Health's recent struggles to gain FDA approval for their new drug candidate.
Lastly, we have Cassava Sciences Inc (SAVA), which saw Perceptive Advisors LLC sell all their put options, resulting in a decrease from 0 to 150,000 shares. This could indicate that Perceptive Advisors LLC is no longer interested in investing in Cassava Sciences' Alzheimer's disease treatments.
In conclusion, Perceptive Advisors LLC's Q3 to Q4 2022 holdings comparison shows a mix of bullish and bearish investments in the biotech industry. While some companies saw an increase in shares owned, others saw a significant decrease. Only time will tell if these investments pay off, but it's clear that Perceptive Advisors LLC has high expectations for some of the companies in their portfolio.
Other Posts
- Exploring Strategic Shifts: Nepsis Inc.'s Investment Moves from Q4 2023 to Q1 2024
- A Look at Wilkins Investment Counsel Inc's Q3 vs. Q4 2022 13F Holdings
- The Rise and Fall of Mercer Capital Advisers' Holdings: A Q2 2021 vs. Q3 2021 Analysis
- Unveiling Northwest Capital Management's Latest Strategic Moves: Q4 2023 to Q1 2024 Insight
- Analyzing CAPROCK Group's Q3 vs. Q4 2022 Holdings: Which Companies Saw Significant Changes?
- **Kevin Kwilinski Joins Berry Global as New CEO to Drive Growth and Innovation in Packaging Solutions**
- The Top Winners and Losers of Clarkston Capital Partners' Q3 and Q4 2022 13F Holdings
- Investing in SPY: A Look at the Ramsey Quantitative Systems Q3 2022 vs Q4 2022 13F Holdings Comparison
- Stralem & Co Inc Q1 2020 vs. Q2 2020 13F Holdings Comparison
- Eagle Ridge Investment Management Q1 2023 vs. Q2 2023 13F Holdings Comparison